Research Associate, AMP-Seq
- Employer
- Intellia Therapeutics
- Location
- Cambridge, MA
- Start date
- Aug 2, 2024
View more categoriesView less categories
- Discipline
- Regulatory, Research/Documentation, Science/R&D, Research
- Required Education
- Bachelors Degree
- Position Type
- Full time
- Hotbed
- Genetown, Best Places to Work
Job Details
Why Join Intellia?
Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.
We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.
Research Associate, AMP-Seq
We are looking for a motivated Research Associate to join our NGS amplicon sequencing production team within the cross functional Genomics Innovation group.
As a Research Associate, you will help run the Amplicon Sequencing (AMP-Seq) queue, which enables the company to evaluate gene editing outcomes for a variety of programs. In executing weekly AMP-Seq runs, you will support this central and critical process that helps advance potentially life changing CRISPR/Cas9-based therapeutics while learning more about NGS library prep and sequencing and liquid handling automation. AMP-Seq is central to Intellia, generating opportunities to work with research and early development teams, exploring a wide range of gene editing applications. Additionally, you will drive ongoing AMP-Seq related process improvement projects through hands on experimental work and in collaboration with the broader Genomics Innovation group. In this role, you will:
- Work with the Amp-seq team on the day-to-day running of the high throughput AMP-Seq library construction and sequencing workflows, meeting weekly turnaround time deadlines
- Work with liquid handling automation to support high throughput workflows
- Operating and maintaining Illumina NextSeq2000 instrument
- Collaborate with the team lead, team members, automation team, and programs/platform teams on AMP-Seq projects
- Experimentally test and implement proposed process improvements for amplicon sequencing
- Troubleshoot process issues and review metrics for passing specifications, in collaboration with the team lead and other group members
- Present work at project team meetings
About You:
The successful candidate will have a passion for lab work with a detail and process-oriented mindset. Successful applicants will also be interested in automation, high throughput workflows, genomics, and gene editing. Candidates must have enthusiasm to learn, grow, and work as part of a cross-functional team.
- BS in Molecular Biology or related field with relevant lab work experience such as an internship or co-op at a biotech/pharma company or work in an academic research lab
- Experience with molecular biology techniques such as gel electrophoresis, PCR, DNA purification, adapter ligation, bead-based clean up, and/or sequencing
- Strong interest in genomics, NGS, and gene editing. Previous experience with Illumina NGS or PacBio long read sequencing would be a bonus.
- Some experience with liquid handling automation (ideally Hamilton) is preferred
- Proficient in following, maintaining and writing SOPs
- Strong time management and process-oriented thinking
- Conscientious record keeping, experience maintaining an electronic lab notebook
Meet your future team
The team is focused on NGS applications for research and early development at Intellia. Much of the work supports the development of new editing technologies, guide RNA/mRNA/delivery modality screening, on- and off-target genome editing characterization of lead drug candidates. The team is working onsite to execute NGS workflows in a wet-lab environment. Therefore, we require a candidate to be local to Cambridge MA, or open to relocating. Our team is focused on building technical expertise and a deepening understanding of genomics in junior scientists interested in a career in therapeutic biotechnology. We work to foster an environment for exploration and growth. In this role, you can expect to join a team of hardworking, supportive, and curious scientists in a collaborative environment.
Covid-19 Vaccination Policy:All Intellia employees, regardless of work location, are expected to follow all applicable federal, state, and local public health regulations and guidelines, and are strongly encouraged to follow all public health recommendations, including being vaccinated for COVID-19.
EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Company
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.
Change life stories with genome editing therapies!
Stock Symbol: NTLA
- Website
- http://intelliatx.com/
- Phone
- (857) 285-6200
- Location
-
40 Erie Street
Cambridge
Massachusetts
02139
US
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert